PREVIEW

New Pancreatic Cancer Vaccine Shows Promise in Early Trial, Offering Fresh Hope for Patients. A new vaccine for pancreatic cancer has shown potential in early trials, slowing disease progression and increasing survival rates. The vaccine was tested in a phase 1 trial involving 20 pancreatic cancer patients and five with bowel cancer. Researchers developed the vaccine to help the immune system target cancer cells with a mutation in the KRAS gene, which plays a key role in tumour growth. In the trial, 68% of patients showed a strong immune response to mutant KRAS tumour proteins after 20 months. Patients with the strongest immune responses lived longer and remained cancer-free longer than those with weaker responses. Pancreatic cancer patients who received the vaccine survived about 2.5 years, much longer than the typical survival of one year. The vaccine can be produced in bulk, making it easier to distribute to a larger number of patients quickly. Experts are calling the early trial results "remarkable" and are excited to continue testing the vaccine's effectiveness. The second phase of the trial is already underway, with a larger group of patients being tested for the jab’s efficacy. The results offer fresh hope for pancreatic cancer patients, who traditionally face poor survival rates due to late detection and ineffective treatments.
Instructions: THIS VIDEO MUST NOT BE EDITED FOR LENGTH TO COMBINE WITH OTHER CONTENT